Previous Close | 8.98 |
Open | 8.97 |
Bid | 8.00 |
Ask | 8.60 |
Strike | 77.50 |
Expire Date | 2026-01-16 |
Day's Range | 8.96 - 8.98 |
Contract Range | N/A |
Volume | |
Open Interest | 83 |
Pediatrix's (MD) Q1 results benefit from higher same-unit revenues, resulting from growing patient volumes, partly offset by high costs. It continues to expect 2024 adjusted EBITDA within $200-$220 million.
Uvalde Consolidated Independent School District (UCISD) today announced that students will have access to virtual health care through a partnership with Hazel Health, a leading telehealth provider, and Superior HealthPlan (Superior), the Texas-based subsidiary of Centene Corporation (NYSE: CNC). Thanks to an investment of $250,000 from Superior, all UCISD students will have access to Hazel Health's high-quality care – at school and at home – through the 2028–2029 school year. The service will be
Select Medical (SEM) revises its adjusted EBITDA guidance upward between $845 million and $885 million for 2024, the mid-point is higher than $807.4 million in 2023.